Bailes new ASCO Foundation chair

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

Bailes new ASCO Foundation chair

ALEXANDRIA, Virginia—Joseph Bailes, MD, editor of Cancer Care & Economics, has been named the new chair of the board of directors of The ASCO Foundation, which works with ASCO to raise and distribute funds for programs that improve cancer care and create an environment for prevention and cure.

A former president of ASCO from 1999 to 2000, Dr. Bailes is a nationally recognized leader in cancer public policy and will continue to serve as co-chair of the ASCO Government Relations Council.

"This is an exciting time in the field of clinical oncology as cancer research and treatments continue to progress, and we are helping to improve the lives of those living with cancer," Dr. Bailes said. "Working with The ASCO Foundation's remarkable staff and board of directors is a wonderful opportunity, and I look forward to supporting continued advancement in the field of oncology in my new role as chair."

Articles in this issue
BRCA1 overexpression is strongly linked to poor outcome in NSCLC patients treated with cisplatin
Bill aims to 'revitalize' FDA by adding powers and databases
New myeloma trial results; two new studies initiated
Neoadjuvant trastuzumab increases pCR rates
Court rejects right of terminally ill to unproven drugs
Sorafenib improves overall survival in Asian HCC pts
Skipping tam doses increases risk of death
The SGR: The madness behind physician payment fee cuts
Dr. Pegram seeks new breast cancer challenges at Miami
SearchMedica.com receives award
FDA adds survival data to Erbitux product labeling
Colon ca chemo: Sequencing or upfront combinations?
FDA oks Campath as first-line Rx of B-CLL
Merck to donate 3 million doses of Gardasil to poor countries
Remembering Hopkins' Martin D. Abeloff, MD, scientist, educator, leader
Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Novel Immunotherapy Achieves Responses/RFS in High-Risk, BCG-Unresponsive NMIBC

Tim Cortese
December 5th 2025
Article

The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL

Tim Cortese
December 5th 2025
Article

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care

ONCOLOGY Staff
December 5th 2025
Article

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Tim Cortese
December 4th 2025
Article

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.